An Impediment to Personalized Medicine Commercialization is the Lack of Understanding of the Value of the Testing
Requires Subscription or Fee PDF


Personalized Medicine
Molecular Diagnostics


Over the past 20 years there have been tremendous advancements in technology in areas such as imaging, medicinal chemistry, data integration, the digitization of medical records, computing power and yet the medical delivery model is largely unchanged. The healthcare community now has a treasure chest of new tools that should permit it to be much more proactive, effective and thus produce improved outcomes at lower costs. Personalized medicine (PM), also called Precision Medicine by some, is the category in which all of these new tools can be grouped. While there are a myriad of reasons such as legacy infrastructure, lack of incentives, costs of adopting new technologies,  one of  the major reasons, is the lack of understanding of the value of such testing  by payers. Moving to a value based pricing model for diagnostic testing will increase adoption rate of PM, raise reimbursement rates for PM testing and improve quality of care at a lower cost for patients.  The end result of this will be tests that have a demonstrated benefit in PM business models and result in the acceleration of commercialization.
Requires Subscription or Fee PDF


Source: World Health Organization Factsheet No 319

Source: 2015 Global life sciences outlook Adapting in an era of transformation

Unless specified by prior arrangement, the author agrees to the following terms and assurances:

  1. For myself and on behalf of the other authors listed on this work, I assign to thinkBiotech LLC the copyright* in the contribution for the full term throughout the world.
  2. I/we further give to the following assurances
    1. I am the sole author of the contribution, or, if not, I have the written authority of the other authors to transfer the copyright* to thinkBiotech LLC and give these warranties;
    2. I and (where appropriate) the other authors are entitled to transfer the copyright to thinkBiotech LLC and no one else would be entitled to prevent us from publishing the contribution;
    3. To the best of my/our knowledge, all the facts in the contribution are true and accurate;
    4. The content of the contribution is entirely original to me (and where appropriate to the other authors) or, if not, the written permission of the owner of the copyright in any material copied from elsewhere has been obtained for all media (all such permissions to be attached to the contribution as supplementary files);
    5. Nothing in the contribution is obscene or libellous;
    6. Nothing in the contribution infringes any duty of confidentiality which I/or the other authors may owe to anyone else.
    7. I and/or the other authors have obtained the appropriate clearances from my/our employer(s) or other concerned institution(s).
* Works by US government employees prepared as part of official duties are in the public domain and the authors are therefore exempt from copyright assignment.